WP
CERO

Woodline Partners’s CERo Therapeutics CERO Stock Holding History

Woodline Partners’s Portfolio CERO Stock Details CERO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-150
Closed -$3.01M – 834
2022
Q2 		$3.01M Buy
150
+137
+1,054% +$2.74M 0.05% 333
2022
Q1 		$250K Hold
13
– – ﹤0.01% 539
2021
Q4 		$248K Buy
+13
New +$258K ﹤0.01% 581

Other funds holding CERO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.62% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.76% 1-Year Est. Return

Woodline Partners's CERO Position: Q3 2022 in Review

Woodline Partners sold out of CERo Therapeutics (CERO) in Q3 2022, closing a stake of 150 shares — an estimated $3.01M sold.

Woodline Partners first reported a position in CERO in Q4 2021 and held it in 3 quarters. The position peaked at $3.01M in Q2 2022. 65 funds tracked by Wall St. Rank hold CERO as of Q3 2022.

  • Woodline Partners reported no remaining CERo Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Woodline Partners sold 150 CERo Therapeutics shares in Q3 2022, an estimated $3.01M.
  • Woodline Partners first reported a position in CERo Therapeutics in Q4 2021 and held it in 3 quarters.
  • Woodline Partners's CERo Therapeutics position peaked at $3.01M in Q2 2022.
  • 65 funds tracked by Wall St. Rank held CERo Therapeutics as of Q3 2022.

Based on Woodline Partners's 13F filing for Q3 2022, filed 14 Nov 2022.